In this episode of The Sunday BBQ, Kevin Hornsby is joined by Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS), to discuss the Company’s latest progress across its mental health and addiction treatment pipeline. Anthony outlines the £1 million investment from key shareholders to accelerate Solvonis’ AI-driven CNS drug discovery programme, as well as the initiation of pivotal translational studies for SVN‑002 — a novel treatment for Alcohol Use Disorder — ahead of a Phase 2b trial in the US. We also explore the company’s strategic use of the FDA’s 505(b)(2) pathway and why its differentiated pipeline continues to attract attention in the neuropsychiatry space.

This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.